118 related articles for article (PubMed ID: 38110844)
1. Bioequivalence study followed by model-informed dose optimization of a powder for oral suspension of 6-mercaptopurine.
Arun B; Joshi M; Kakkar AK; Madki S; Ivaturi V; Chinnaswamy G; Banavali S; Gota V
Pediatr Blood Cancer; 2024 Mar; 71(3):e30813. PubMed ID: 38110844
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Larsen RH; Hjalgrim LL; Grell K; Kristensen K; Pedersen LG; Brünner ED; Als-Nielsen B; Schmiegelow K; Nersting J
Cancer Chemother Pharmacol; 2020 Jul; 86(1):25-32. PubMed ID: 32519032
[TBL] [Abstract][Full Text] [Related]
3. A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients - results of a randomized clinical trial.
Hanff LM; Mathot RA; Smeets O; Postma DJ; Ramnarain S; Vermes A; Pieters R; Zwaan CM
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):653-62. PubMed ID: 24800919
[TBL] [Abstract][Full Text] [Related]
4. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
6. DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.
Ju HY; Lee JW; Cho HW; Hyun JK; Ma Y; Yi ES; Yoo KH; Sung KW; Choi R; Koo HH; Lee SY
PLoS One; 2021; 16(1):e0245667. PubMed ID: 33481917
[TBL] [Abstract][Full Text] [Related]
7. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children.
Mawatari H; Unei K; Nishimura S; Sakura N; Ueda K
Pediatr Int; 2001 Dec; 43(6):673-7. PubMed ID: 11737747
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and bioequivalence comparison of a single 100-mg dose of cefteram pivoxil powder suspension and tablet formulations: a randomized-sequence, open-label, two-period crossover study in healthy Chinese adult male volunteers.
Zou J; Di B; Wu CY; Hu Q; Li JH; Zhu Y; Fan H; Xiao D; Wang GJ
Clin Ther; 2008 Apr; 30(4):654-60. PubMed ID: 18498914
[TBL] [Abstract][Full Text] [Related]
11. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
[TBL] [Abstract][Full Text] [Related]
12. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
Lennard L; Lewis IJ; Michelagnoli M; Lilleyman JS
Med Pediatr Oncol; 1997 Oct; 29(4):252-5. PubMed ID: 9251729
[TBL] [Abstract][Full Text] [Related]
13. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
14. Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.
Keuzenkamp-Jansen CW; De Abreu RA; Blom HJ; Bökkerink JP; Trijbels JM
Biochem Pharmacol; 1996 May; 51(9):1165-71. PubMed ID: 8645339
[TBL] [Abstract][Full Text] [Related]
15. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations.
Lennard L; Keen D; Lilleyman JS
Clin Pharmacol Ther; 1986 Sep; 40(3):287-92. PubMed ID: 3461899
[TBL] [Abstract][Full Text] [Related]
16. Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1.
Hoppmann AL; Chen Y; Landier W; Hageman L; Evans WE; Wong FL; Relling MV; Bhatia S
Cancer; 2021 Oct; 127(20):3832-3839. PubMed ID: 34161608
[TBL] [Abstract][Full Text] [Related]
17. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
Schmiegelow K; Ifversen M
Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
[TBL] [Abstract][Full Text] [Related]
18. Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Barcelos A; Dubbelman B; De Abreu R; Brouwer C; Bökkerink JP; de Haas V; de Groot-Kruseman H; Jansen G; Kaspers GL; Cloos J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):422-33. PubMed ID: 24940700
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
20. Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
Pediatr Blood Cancer; 2016 Apr; 63(4):712-5. PubMed ID: 26878433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
